Business context and reporting period
BioMarin’s October 6, 2026 Form 8-K reports preliminary estimates of the financial impact of its acquisition of Alesta Therapeutics B.V., completed August 31, 2026. The estimates relate to the quarter ended September 30, 2026, and full-year 2026.
Estimated financial impact
| Period | Estimated charges | Estimated diluted EPS impact |
|---|---|---|
| Third quarter 2026 | Approximately $283 million of pre-tax acquired in-process research and development (IPR&D) expense; ongoing operating expenses also contribute to the impact. | Approximately $1.50 unfavorable to both GAAP and non-GAAP diluted EPS. |
| Full year 2026 | Approximately $320 million of total pre-tax charges, including the IPR&D expense and ongoing operating expenses, transaction costs and transition costs. | Approximately $1.55 unfavorable to both GAAP and non-GAAP diluted EPS. |
The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other operating metrics.
Changes versus prior guidance
BioMarin’s full-year 2026 guidance announced August 6, 2026, did not include the Alesta acquisition. The company expects to update its 2026 guidance with its third-quarter results. It does not forecast acquired IPR&D charges because the occurrence, size, and timing of business development transactions are inherently uncertain.
Outlook, uncertainties, and unusual items
Quarterly results are preliminary and unaudited, have not been finalized, and remain subject to the company’s financial statement closing procedures. Actual results may differ. The EPS figures include estimated acquisition-related charges and expenses; acquired IPR&D is a significant unusual item. The filing cautions that forward-looking statements are subject to risks, including procedures to finalize results and risks described in BioMarin’s SEC filings.
BioMarin defines non-GAAP diluted EPS using adjusted non-GAAP income and weighted-average diluted shares. The company cautions that non-GAAP measures are not standardized, should be considered alongside GAAP results, and may not be comparable with similarly titled measures at other companies.
Investor items to verify
- Final third-quarter results and whether the preliminary acquisition-related estimates change.
- The detailed components of the approximately $320 million full-year charge, including IPR&D, operating, transaction, and transition costs.
- Updated full-year 2026 guidance and its GAAP and non-GAAP assumptions.
- The reconciliation and treatment of acquisition-related items in reported GAAP and non-GAAP results.